BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1916-0216
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm ; volume:50 ; number:1 ; day:6 ; month:11 ; year:2021 ; pages:1-8 ; date:12.2021
Journal of otolaryngology, head & neck surgery ; 50, Heft 1 (6.11.2021), 1-8, 12.2021
- Creator
-
Silver, Jennifer A.
Bogatchenko, Mariya
Pusztaszeri, Marc
Forest, Véronique-Isabelle
Hier, Michael P.
Yang, Ji Wei
Tamilia, Michael
Payne, Richard J.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40463-021-00543-9
- URN
-
urn:nbn:de:101:1-2022012020033948986359
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Silver, Jennifer A.
- Bogatchenko, Mariya
- Pusztaszeri, Marc
- Forest, Véronique-Isabelle
- Hier, Michael P.
- Yang, Ji Wei
- Tamilia, Michael
- Payne, Richard J.
- SpringerLink (Online service)
Other Objects (12)
Introduction and expression of PIK3CA E545K in a papillary thyroid cancer BRAF V600E cell line leads to a dedifferentiated aggressive phenotype
False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma
Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells
Mucinous borderline ovarian tumors with BRAF V600E mutation may have low risk for progression to invasive carcinomas
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Prognostic Significance of Various Clinicopathologic Parameters and BRAF V600E Mutation in Papillary Thyroid Microcarcinoma—An Observational Study
Predicting factors of central lymph node metastasis and BRAF V600E mutation in Chinese population with papillary thyroid carcinoma
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas
Clinical and Pathological Features and Gene Expression Profiles of Clinically Aggressive Papillary Thyroid Carcinomas
High-density microarray expression profiling in conventional papillary thyroid carcinomas with versus without a BRAF mutation
Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis
Introduction and expression of PIK3CA E545K in a papillary thyroid cancer BRAF V600E cell line leads to a dedifferentiated aggressive phenotype
False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma
Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells
Mucinous borderline ovarian tumors with BRAF V600E mutation may have low risk for progression to invasive carcinomas
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Prognostic Significance of Various Clinicopathologic Parameters and BRAF V600E Mutation in Papillary Thyroid Microcarcinoma—An Observational Study
Predicting factors of central lymph node metastasis and BRAF V600E mutation in Chinese population with papillary thyroid carcinoma
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas
Clinical and Pathological Features and Gene Expression Profiles of Clinically Aggressive Papillary Thyroid Carcinomas
High-density microarray expression profiling in conventional papillary thyroid carcinomas with versus without a BRAF mutation
Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis
Introduction and expression of PIK3CA E545K in a papillary thyroid cancer BRAF V600E cell line leads to a dedifferentiated aggressive phenotype
False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma
Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells
Mucinous borderline ovarian tumors with BRAF V600E mutation may have low risk for progression to invasive carcinomas
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Prognostic Significance of Various Clinicopathologic Parameters and BRAF V600E Mutation in Papillary Thyroid Microcarcinoma—An Observational Study
Predicting factors of central lymph node metastasis and BRAF V600E mutation in Chinese population with papillary thyroid carcinoma
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas
Clinical and Pathological Features and Gene Expression Profiles of Clinically Aggressive Papillary Thyroid Carcinomas
High-density microarray expression profiling in conventional papillary thyroid carcinomas with versus without a BRAF mutation